share_log

Oppenheimer Assumes Cue Biopharma at Outperform, Announces Price Target of $10

Benzinga ·  Jun 26, 2023 06:50

Oppenheimer analyst Mark Breidenbach assumes Cue Biopharma (NASDAQ:CUE) with a Outperform rating and announces Price Target of $10.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment